Member Info for InsideEdge

Some enormous trades going through. Someone knows something (good or bad). Let’s hope it’s good as the price is holding

Latest valuation for Revolut $75bn. This must impact NAV positively

Have they stopped publishing quarterly NAV? Would have expected this in August

Any insight would be appreciated

I can see sentiment changing quite quickly here. There’s been a summer of uncertainty but this is reducing. With a couple of strong RNS re copper numbers, guidance and partners this could fly. It’s only the uncertainty that caused the drop from 4.5. I think we could get back there or beyond super quick. I’ve got everything crossed that management finally understand investor expectations

Good luck everyone

Looks like sentiment has changed & buys flooding in. Looking positive

Am I missing something? Approx 10m raised at 20% discount = approx 2m

Market cap approx 100m. Therefore discount only represents approximately 2% of MC…. so why is price down 20%?

The second deal is great but also suggests the first is progressing well. For me, and my decision making, this is most significant in reducing potential risk in the platform. The payment also moves the need for additional funding further away for ongoing trials to proceed further without dilution

It’s been a painful period but it always looked as if the fundamentals would come good. Tremendous progress has been made in both process and securing resources. It’s just taken time for the market to believe everything would come together. It certainly appears that the latest update has underpinned this. Where might this go with another solid quarter and increased forecast? Happy times ahead

Large volumes today but price holding 4.50

Fingers crossed this is the floor that the price can recover from

They posted quarterly NAV to March in May. Expected June NAV in August but nothing posted?

From Jan RNS

Exceptional results from the first 13 patients receiving SCIB1 in the ongoing SCOPE trial, with an objective response rate of 85%, indicate a high probability of success in this cohort which should complete in Q2 2024. Recruitment into the iSCIB1+ cohort is expected to be complete by the end of Q2 2024, with early data expected in Q3 2024.

The large purchases have been consistent for a couple of weeks. I wonder if we’re near a holding RNS and the significance of this? Someone’s clearly very keen

500k seller still there but buyers sweeping everything up. Where will price go once seller cleared?

Current share price and recent decline makes no sense to me. Every bit of news takes Scancell closer to commercialisation. The product pipeline is strong. Trials are progressing well with little or no adverse reactions. I can only believe that further news will have a dramatic impact on the price. This is certainly my hope

We are right in the window where drill results could come in at any time. Let’s hope it’s soon and positive news. After so long waiting, it’s so close

Several years ago there was a posting by ‘schoolboy’ (or something similar). This info first encouraged me to invest in BPC. Do any LTHs remember or have access to this?

Back to 100. Just need investor confidence to push price higher now

Prothena�s lead drug has decisively failed a crucial Phase IIb study for rare, second-line cases of AL amyloidosis. And after concluding that their Phase III for frontline use is also headed to failure, the biotech�s executive team is scrapping the whole program.

Discount circa 15%. Let�s hope for a couple of positive updates to change the sentiment here

Seems to be changing here. Discount between price and NAV starting to close. It would be nice to see a premium

Company making good progress but nothing seems to light up this share price. I hate harping back to old money but this was trading at 10p in anticipation of license and future production. Now we have a solid record of performance and improving copper price, sitting at less than 6p is frustrating. Perhaps this is the new reality? Interested in thoughts from other holders